Fascinating New Uses For Psychedelics

Scientists are looking into various medical and psychiatric uses for psychedelics.
Could the taboo be ending?

By Sarah Seltzer, AlterNet
Posted on April 26, 2012

On last week's episode of the drama "Mad Men," set in 1966, Roger Sterling, the embodiment of the classic old-boys club figure, accompanies his younger wife to a dinner party where the guests "turned on" to LSD.

After a night of laughing fits, tears, dancing and hallucinations, the couple have a profound conversation about their marriage's failure. Sterling wakes up the next morning feeling that he's been given an entry into "the truth" and in a shockingly sincere tone, declares that it's going "to be a beautiful day."

The sequence represents a surprisingly positive portrayal of acid, staying away from cliches and demonstrating how a stuck-in-the-mud character might actually, at least temporarily, be jolted out of despair and complacency by an experience on drugs.

In some ways, Roger's fictional night embodies the quintessential mid-'60s "long, strange, trip." For a brief period before LSD became synonymous with the youth-led counterculture, hippies and burnout, it was taken seriously among elites--it was even legal. The drug, originally being tested for various physical and psychological institutions, began to be recreationally used by professionals like the therapist who encourages the Sterlings to "turn on" as aiding personal development and enhancing insight.

But when LSD became a street drug and was criminalized, it moved out of laboratories, and the stigma carried over through the end of the century.

Hallucinogens like LSD and psilocybin were added to the 1970 Controlled Substance Act as Schedule I substances, which defines them as having no medicinal value and makes getting federal funding (or the actual drugs necessary) for research nearly impossible. That is why, even now, many studies of pot and hallucinogens are conducted in other countries. Scientists wanted to conduct the research, but they couldn't, and for the most part, it's still very difficult.

It's taken decades for American scientists, doctors and patients to have the chance to take a closer look at the uses of psychedelic drugs, not just recreational but medical, personal and therapeutic. Even now, doctors who do this work are eager to distance themselves from Timothy Leary and his ilk.

And yet the shift has happened. The profession is back to exploring the various positive effects of these drugs, and their work is being covered by the mainstream media. Here are some examples of ways psychedelics are being explored in medicine today.

1. Alcoholism. This year, a group of Norwegian scientists went back into medical archives to reexamine previous LSD studies to help recovering alcoholics. When they crunched the data, what they found was not only evidence that LSD is useful in treating addiction, but also circumstantial evidence that the culture wars may have derailed the progress of this line of inquiry. From HealthDay's story last month:

In a new analysis, Norwegian researchers examined six studies of LSD and alcoholism that were conducted in the United States and Canada between 1966 and 1970. 

The analysis of data from the 536 patients in the studies showed that a single dose of LSD helped heavy alcoholics quit and reduced their risk of resuming drinking, according to the meta-analysis appearing online March 8 in the Journal of Psychopharmacology. 

Patients who received a full dose of the controversial drug did the best. On average, 59 percent of those patients showed a clear improvement, compared with 38 percent of patients in other groups, the Norwegian University of Science and Technology researchers said.

Kristen Gwynne has pointed out on AlterNet that this study is particularly promising as there are currently very limited options for those who suffer from alcoholism, and 12-step programs, which rely on a loosely religious framework, can be discriminatory and leave people out.

The implications of these studies are huge. As the authors said, "Given the evidence for a beneficial effect of LSD on alcoholism, it is puzzling why this treatment approach has been largely overlooked." In fact, the kind of radical new perspective portrayed on "Mad Men" is the kind of jolt that could help break the hold of the disease. 

2. End-of-life issues. That change in perspective may also help those who are dying or at risk of dying, and in the throes of psychological crisis. The New York Times Magazine recently ran a comprehensive cover story by Lauren Slater describing new trials for patients suffering from terminal or severe disease, and the attendant anxieties.

One patient profiled in the story had a profound emotional catharsis during her controlled use of psilocybin, and described it for posterity on video:

“I felt this lump of emotions welling up...almost like an entity,” Sakuda said, as she spoke straight into the camera. “I started to cry....Everything was concentrated and came welling up and then...it started to dissipate, and I started to look at it differently....I began to realize that all of this negative fear and guilt was such a hindrance...to making the most of and enjoying the healthy time that I’m having.” Sakuda went on to explain that, under the influence of the psilocybin, she came to a very visceral understanding that there was a present, a now, and that it was hers to have.

Slater's piece contains other compelling personal anecdotes from deeply ill patients, taking part in similar or parallel studies. After the directed, controlled administration of psychedelics, their fear of death decreased, their feeling of transcendence increased. Most importantly their anxiety was lessened, an alteration which positively affected their health and well-being.

3. Depression and anxiety. Slater's Times story also begins to dig into the physical reasons that psychedelics might have this effect--they may shut down over-active regions of the brain that are associated with depression:

The researchers found that the states of “unrestrained consciousness” that accompany the ingestion of psilocybin are associated with a deactivation of regions of the brain that integrate our senses and our perception of self. In depressed people, Nutt explains, one of those regions, the anterior cingulate cortex, is overactive, and psilocybin may work to shut it down. Nutt is planning a study in which he will give psilocybin to individuals with treatment resistant depression and see whether the drug can ease some of depression’s most recalcitrant symptoms.

That such an experiment would take place is logical; it seems evident that given the indications for these drugs' interaction with the depression and anxiety faced by terminal patients, they might also help those suffering from anxiety at other phases of life.


4. Cluster headaches. One interesting, more physical indication for these drugs--which arises from their non-hallucinogenic properties--is for the treatment of cluster headaches, which some call "suicide headaches" due to their extremely painful, frequent nature.

In 2009, the Daily Beast wrote about Bob Wold, a cluster headache sufferer, and the first time he took magic mushrooms (psilocybin):

The psychedelics arrived in a brown box at his doorstep from a long-distance dealer. He took one dose: about 1.5 grams. "In 15 minutes I could feel the difference,” he says. “My head was clearer than it had probably been in the past 20 years. Other medications felt like they were just covering it up.” But on acid, “All the pressure was gone."

Wold decided to help fund research into the uses of psychedelics on headaches like his:

Cluster Busters, a nonprofit advocacy group co-founded by Wold, is funding research by Harvard’s Dr. John Halpern, who recently administered a modified LSD molecule to a handful of cluster patients, successfully ending most of their headache cycles for weeks or months. Halpern thinks they may have finally found the cure for an ailment that has mystified physicians for years, and hopes to run a larger clinical trial soon.

Harvard’s Dr. John Halpern recently administered a modified LSD molecule to patients, successfully ending most of their headache cycles.

5. Post-traumatic stress disorder (PTSD). MDMA, the psychedelic ingredient in the drug Ecstasy has been studied recently to treat a specific form of depression and anxiety: that associated with past trauma. Oprah Magazine profiled several women who had been abused or raped and underwent experimental MDMA therapy. Their reactions were varied, but mostly positive. Here's one:

"I used to think, I'm a broken person. I'll never be able to do this simple thing. But after my first session, I thought, Well, it's okay not to stand in line. It's okay to go early. I stopped judging myself, and I didn't avoid my life anymore. Which was wonderful." A quarter-century after taking MDMA, Ot'alora still gets triggered from time to time, particularly in crowded places. "But it's much more short-lived now," she says. "Sometimes it's a matter of a second before I bring my body back to a safe zone."

Here's another:

In 2008 Emily did a single session of MDMA with the guidance of an underground therapist. "I took myself through the rape and I felt the trauma deeply, but I also stepped outside of it," she says. "I had what they call the 'God view' in a computer game. I saw it objectively, and with compassion. I wasn't thinking, I shouldn't have been there or I'm a piece of crap or This is all my fault."

The LA Times reported on a study being run by clinical investigator and psychiatrist Michael Mithoefer of South Carolina, the man who conducted the most recent round of MDMA therapy experiments:

Mithoefer has received FDA permission to test whether Ecstasy can help Iraq and Afghanistan veterans overcome their PTSD when used during psychotherapy sessions; six veterans have enrolled in the study. In an earlier clinical trial, Ecstasy helped 10 of 12 women recover from PTSD stemming from child sexual trauma. Only 2 out of 8 women who took a placebo had similar results, Mithoefer reported last year in the Journal of Psychopharmacology.

With MDMA as well as with mushrooms and LSD, the commonly known effects of the drug for recreational use can be seen in the way it's used to target particular psychological conditions.

Ecstasy's reputation for enhancing trust has clear roots in its biological effect. Using brain scans, Columbia University psychologist Gillinder Bedi found that subjects who took MDMA showed heightened activity in a brain region associated with processing rewards and depressed activity in the amygdala — a source of fear reactions. In animals, MDMA boosts the hormone oxytocin, which promotes trust, sociability and interpersonal attachment.

The politics of testing and studying the positive medical effects of psychedelics are marked by the politics of the drug war, the culture war, the pharmaceutical industries and academia.There may be no interest from Big Pharma to lobby the government for these studies because of the lack of profit potential; these drugs are something you take once or twice, not daily, and they are not patented.

But as all these stories in the mainstream media show, the therapeutic uses of these substances may finally be getting the kind of measured, rational attention they deserve--without the handwringing that comes from past negative associations. At least we can hope.

Here's a  National Geographic video about the return of LSD to the lab:

Magic mushroom’s positive effects lasting over a year, say researchers

By Eric W. Dolan - RAW Story

Scientists at the Johns Hopkins University School of Medicine claim to have determined the proper dose levels needed to create positive changes in attitudes, mood, life satisfaction, and behavior that persist for more than a year with the psychoactive substance in so-called “magic mushrooms.”

The findings are the latest in a series of experiments done at Johns Hopkins to investigate psilocybin, a psychedelic substance contained in certain mushrooms. The findings were published online this week in the peer-reviewed journal Psychopharmacology.

“In cultures before ours, the spiritual guide or healer had to discern how much of what type of mushroom to use for what purposes, because the strength of psychoactive mushrooms varies from species to species and even from specimen to specimen,” said Roland Griffiths, Ph.D., a professor of psychiatry and behavioral sciences and neuroscience at the Johns Hopkins University School of Medicine and the study’s lead scientist.

“In our laboratory, weʼre working with the pure chemical psilocybin, which we can measure out precisely,” he added. “We wanted to take a methodical look at how its effects change with dosage. We seem to have found levels of the substance and particular conditions for its use that give a high probability of a profound and beneficial experience, a low enough probability of psychological struggle, and very little risk of any actual harm.”

SIMILAR: First therapeutic study of LSD in 35 years finishes treatment of last subject

The researchers said 94 percent of the study’s 18 participants rated their experiences with psilocybin as among the top five most or as the top most spiritually significant experience of his or her life at a 14-month follow-up. Eighty-four percent also reported positive changes in their behaviors, changes like improved relationships with family and others, increased physical and psychological self-care, and increased devotion to spiritual practice, which were corroborated by family members and others.

“I feel that I relate better in my marriage,” one participant reported. “There is more empathy – a greater understanding of people and understanding their difficulties and less judgment.”
The participants, ages 29 to 62, were screened to include only those who were deemed psychologically and physically healthy. Each participant received five closely-monitored, eight-hour psilocybin sessions a month apart. Each session had a different dose of psilocybin, with one session using a placebo, and was “blind,” meaning neither the participants, the monitors, nor the scientists knew how much psilocybin – if any – had been given during any session.

At higher doses of psilocybin, nearly a third of the participants experienced great fear or had delusions, but with gentle guidance from researchers, those reactions did not outlast the psilocybin session or harm the participants. Those who received lower doses of the psychedelic before the higher doses were the most likely to have long-lasting positive changes in attitudes and behavior.

Potential psychotherapeutic value of ‘magic mushrooms’
“The Hopkins psilocybin studies clearly demonstrate that this route to the mystical is not to be walked alone,” Jerome Jaffe, M.D., who served as the first White House “Drug Czar,” commented. “But they have also demonstrated significant and lasting benefits.”

“That raises two questions: Could psilocybin-occasioned experiences prove therapeutically useful, for example in dealing with the psychological distress experienced by some terminal patients? And should properly-informed citizens, not in distress, be allowed to receive psilocybin for its possible spiritual benefits, as we now allow them to pursue other possibly risky activities such as cosmetic surgery and mountain-climbing?”

A similar study published in the Archives of General Psychiatry in January found psilocybin can safely improve the moods of patients with advanced-stage cancer and anxiety.

The study was headed by Dr. Charles S. Grob, a professor of psychiatry at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and found a significant improvement of mood and a reduction in symptoms of anxiety up to six months after receiving psilocybin-assisted therapy.

“We are working with a patient population that often does not respond well to conventional treatments,” said Grob. “Following their treatments with psilocybin, the patients and their families reported benefit from the use of this hallucinogen in reducing their anxiety. This study shows psilocybin can be administered safely, and that further investigation of hallucinogens should be pursued to determine their potential benefits.”

Although some may be concerned that a relatively unstudied and illegal substance such as psilocybin could pose health risks, a study published in the Psychopharmacology in 2004 found there is “no cause for concern that [psilocybin] is hazardous with respect to somatic health” in healthy adults.

The only physiological side-effects the study found was a brief increase in blood pressure and a small increase in levels of thyroid-stimulating-hormone (TSH), prolactin, cortisol, and adrenocorticotropic hormone. None of these side-effects were considered dangerous to healthy adults.

“Typically, the experiences after [medium and high doses of psilocybin] were rated positive, with retrospective statements ranging from ‘pleasurable’ to ‘ineffably beautiful,’ ” according to the study. One volunteer had a fearful experience after being given a high dose of psilocybin, but his anxiety was resolved without the need for pharmacological intervention.

“We know that psilocybin is remarkably non-toxic to the bodyʼs organ systems,” Matthew Johnson, Ph.D., an assistant professor of psychiatry and behavioral sciences at Johns Hopkins and lead author of an earlier Hopkins paper on hallucinogen safety remarked. “But there are indirect risks: if someone experiences high anxiety, fear, or paranoia during a psilocybin session, itʼs not hard to imagine them behaving in ways harmful to themselves or others.”

“These risks appear to be minimized when volunteers develop a trusting relationship with a skilled monitor, who remains present with them for the duration of the substanceʼs primary effects, and who is available afterwards for consultation.”

Researchers: Psilocybin Mushrooms' Positive Effects Last Over a Year

By Eric W. Dolan - RAW Story
Wednesday, June 15th, 2011

Scientists at the Johns Hopkins University School of Medicine claim to have determined the proper dose levels needed to create positive changes in attitudes, mood, life satisfaction, and behavior that persist for more than a year with the psychoactive substance in so-called "magic mushrooms."

The findings are the latest in a series of experiments done at Johns Hopkins to investigate psilocybin, a psychedelic substance contained in certain mushrooms. The findings were published online this week in the peer-reviewed journal Psychopharmacology.

“In cultures before ours, the spiritual guide or healer had to discern how much of what type of mushroom to use for what purposes, because the strength of psychoactive mushrooms varies from species to species and even from specimen to specimen," said Roland Griffiths, Ph.D., a professor of psychiatry and behavioral sciences and neuroscience at the Johns Hopkins University School of Medicine and the study's lead scientist.

"In our laboratory, weʼre working with the pure chemical psilocybin, which we can measure out precisely," he added. "We wanted to take a methodical look at how its effects change with dosage. We seem to have found levels of the substance and particular conditions for its use that give a high probability of a profound and beneficial experience, a low enough probability of psychological struggle, and very little risk of any actual harm."

The researchers said 94 percent of the study's 18 participants rated their experiences with psilocybin as among the top five most or as the top most spiritually significant experience of his or her life at a 14-month follow-up. Eighty-four percent also reported positive changes in their behaviors, changes like improved relationships with family and others, increased physical and psychological self-care, and increased devotion to spiritual practice, which were corroborated by family members and others.

"I feel that I relate better in my marriage," one participant reported. "There is more empathy – a greater understanding of people and understanding their difficulties and less judgment."

The participants, ages 29 to 62, were screened to include only those who were deemed psychologically and physically healthy. Each participant received five closely-monitored, eight-hour psilocybin sessions a month apart. Each session had a different dose of psilocybin, with one session using a placebo, and was "blind," meaning neither the participants, the monitors, nor the scientists knew how much psilocybin - if any - had been given during any session.

At higher doses of psilocybin, nearly a third of the participants experienced great fear or had delusions, but with gentle guidance from researchers, those reactions did not outlast the psilocybin session or harm the participants. Those who received lower doses of the psychedelic before the higher doses were the most likely to have long-lasting positive changes in attitudes and behavior.

Potential psychotherapeutic value of 'magic mushrooms'

"The Hopkins psilocybin studies clearly demonstrate that this route to the mystical is not to be walked alone," Jerome Jaffe, M.D., who served as the first White House "Drug Czar," commented. "But they have also demonstrated significant and lasting benefits."

"That raises two questions: Could psilocybin-occasioned experiences prove therapeutically useful, for example in dealing with the psychological distress experienced by some terminal patients? And should properly-informed citizens, not in distress, be allowed to receive psilocybin for its possible spiritual benefits, as we now allow them to pursue other possibly risky activities such as cosmetic surgery and mountain-climbing?"

A similar study published in the Archives of General Psychiatry in January found psilocybin can safely improve the moods of patients with advanced-stage cancer and anxiety.

The study was headed by Dr. Charles S. Grob, a professor of psychiatry at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and found a significant improvement of mood and a reduction in symptoms of anxiety up to six months after receiving psilocybin-assisted therapy.

"We are working with a patient population that often does not respond well to conventional treatments," said Grob. "Following their treatments with psilocybin, the patients and their families reported benefit from the use of this hallucinogen in reducing their anxiety. This study shows psilocybin can be administered safely, and that further investigation of hallucinogens should be pursued to determine their potential benefits."

Although some may be concerned that a relatively unstudied and illegal substance such as psilocybin could pose health risks, a study published in the Psychopharmacology in 2004 found there is "no cause for concern that [psilocybin] is hazardous with respect to somatic health" in healthy adults.

The only physiological side-effects the study found was a brief increase in blood pressure and a small increase in levels of thyroid-stimulating-hormone (TSH), prolactin, cortisol, and adrenocorticotropic hormone. None of these side-effects were considered dangerous to healthy adults.

"Typically, the experiences after [medium and high doses of psilocybin] were rated positive, with retrospective statements ranging from ‘pleasurable’ to ‘ineffably beautiful,’ " according to the study. One volunteer had a fearful experience after being given a high dose of psilocybin, but his anxiety was resolved without the need for pharmacological intervention.

"We know that psilocybin is remarkably non-toxic to the bodyʼs organ systems," Matthew Johnson, Ph.D., an assistant professor of psychiatry and behavioral sciences at Johns Hopkins and lead author of an earlier Hopkins paper on hallucinogen safety remarked. "But there are indirect risks: if someone experiences high anxiety, fear, or paranoia during a psilocybin session, itʼs not hard to imagine them behaving in ways harmful to themselves or others."

"These risks appear to be minimized when volunteers develop a trusting relationship with a skilled monitor, who remains present with them for the duration of the substanceʼs primary effects, and who is available afterwards for consultation."

SIMILAR: First therapeutic study of LSD in 35 years finishes treatment of last subject

New research restores psychedelics’ medical respectability

By Eric W. Dolan Tuesday, September 7th, 2010

Recently published studies suggest that 'magic mushrooms' and 'ecstasy' may have medical value.

Before the enactment of the Controlled Substances Act in the late 60's, psychiatrists had been eagerly investigating the use of psychedelic drugs as an aid to psychological therapy.

Unfortunately, as the government sought to eliminate the recreational use of these drugs, it consequentially eliminated nearly all research into their effects.

Although there was almost no research on psychedelic drugs from the early 70's to late 90's, within the last decade studies have reaffirmed that 'magic mushrooms' and ecstasy (MDMA) can be valuable tools for mental health professionals.

A study published in the Archives of General Psychiatry found psilocybin, the active substance in 'magic mushrooms,' can safely improve the moods of patients with advanced-stage cancer and anxiety.

The study was headed by Dr. Charles S. Grob, a professor of psychiatry at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center.

In Dr. Grob's study, twelve volunteers, ages 36 to 58, with advanced-stage cancer and anxiety were given a moderate dose of psilocybin and, on a separate occasion, a placebo. The study employed a double-blind procedure, meaning neither the volunteers nor the researchers monitoring them knew whether they'd been given a placebo or psilocybin.

After receiving a dose of psilocybin or a placebo, volunteers were monitored for six hours. They were encouraged to lie in bed, wear eye shades and listen to soft music during the first few hours after ingesting the medication or the placebo. The volunteers were then interviewed after the six-hour session and over the next six months to assess the consequences of the treatment.

The study found a significant improvement of mood and a reduction in symptoms of anxiety up to six months after receiving psilocybin-assisted therapy.

"We are working with a patient population that often does not respond well to conventional treatments," said Dr. Grob. "Following their treatments with psilocybin, the patients and their families reported benefit from the use of this hallucinogen in reducing their anxiety. This study shows psilocybin can be administered safely, and that further investigation of hallucinogens should be pursued to determine their potential benefits."

Although some may be concerned that a relatively unstudied and illegal substance such as psilocybin may pose health risks, a study published in the peer-reviewed journal Psychopharmacology in 2004 found there is "no cause for concern that [psilocybin] is hazardous with respect to somatic health" in healthy adults.

The only physiological side-effects the study found was a brief increase in blood pressure and a small increase in levels of thyroid-stimulating-hormone (TSH), prolactin, cortisol, and adrenocorticotropic hormone. None of these side-effects were considered dangerous to healthy adults.

"Typically, the experiences after [medium and high doses of psilocybin] were rated positive, with retrospective statements ranging from ‘pleasurable’ to ‘ineffably beautiful,’ " according to the study. One volunteer had a fearful experience after being given a high dose of psilocybin, but his anxiety was resolved without the need for pharmacological intervention.

Recently published research has also found Methylene-dioxy-methamphetamine (MDMA), better known as the club drug esctasy, to be a viable treatment for Post-Traumatic Stress Disorder (PTSD).

The study was headed by Michael C. Mithoefer and published in the peer-reviewed Journal of Psychopharmacology.

For their study, Mithoefer and his colleagues recruited twenty people who suffered from chronic PTSD. The majority of the participants in this study were women and had been diagnosed with PTSD for an average of 19 years.

Of these twenty participants, twelve were randomly assigned to receive MDMA-assisted therapy while the remaining eight were assigned to receive the same psychotherapy, but with a placebo pill instead of ecstasy.

The psychotherapy consisted of two, eight hour sessions at an outpatient office.

The method of psychotherapy used followed principles similar to those developed by Dr. Humphry Osmond, Dr. Stansilav Grof, and others in the 50's and 60's for LSD psychotherapy.

There was a significant difference between the group of participants who received ecstasy-assisted therapy and those who received psychotherapy without ecstasy.
Volunteers treated with a combination of MDMA and psychotherapy saw clinically and statistically significant improvements in their PTSD – over 80% of the trial group no longer met the diagnostic criteria for PTSD, stipulated in the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV-TR) following the trial, compared to only 25% of the placebo group.

In addition, all three volunteers who reported being unable to work due to PTSD were able to return to work following treatment with MDMA.

Mithoefer and his colleagues believe that the use of ecstasy during psychotherapy may be effective because it allows the patient to emotionally engage traumatic memories without becoming overwhelmed by fear or anxiety.

"The goal of using MDMA is to temporarily reduce fear and increase trust without inhibiting emotions, especially painful emotions, allowing these patients a window where psychotherapy for their PTSD is effective."

Due to the preliminary nature of the study, these findings are limited, but Mithoefer and his colleagues are enthusiastic that long-term research will show similarly positive results.

"Renaissance" of psychedelic research

Science at ‘the end of the beginning of the renaissance’ of psychedelic research

By The Associated Press
Sunday, April 25th, 2010

The big white pill was brought to her in an earthenware chalice. She'd already held hands with her two therapists and expressed her wishes for what it would help her do.

She swallowed it, lay on the couch with her eyes covered, and waited. And then it came.

"The world was made up of jewels and I was in a dome," she recalled. Surrounded by brilliant, kaleidoscopic colors, she saw the dome open up to admit "this most incredible luminescence that made everything even more beautiful."

Tears trickled down her face as she saw "how beautiful the world could actually be."

That's how Nicky Edlich, 67, began her first-ever trip on a psychedelic drug last year.

She says it has greatly helped her psychotherapeutic treatment for anxiety from her advanced ovarian cancer.

And for researchers, it was another small step toward showing that hallucinogenic drugs, famous but condemned in the 1960s, can one day help doctors treat conditions like cancer anxiety and post-traumatic stress disorder.

The New York University study Edlich participated in is among a handful now going on in the United States and elsewhere with drugs like LSD, MDMA (Ecstasy) and psilocybin, the main ingredient of "magic mushrooms." The work follows lines of research choked off four decades ago by the war on drugs. The research is still preliminary. But at least it's there.

"There is now more psychedelic research taking place in the world than at any time in the last 40 years," said Rick Doblin, executive director of the Multidisciplinary Association for Psychedelic Studies, which funds some of the work. "We're at the end of the beginning of the renaissance."

He said that more than 1,200 people attended a conference in California last weekend on psychedelic science.

But doing the research is not easy, Doblin and others say, with government funders still leery and drug companies not interested in the compounds they can't patent. That pretty much leaves private donors.

"There's still a lot of resistance to it," said David Nichols, a Purdue University professor of medicinal chemistry and president of the Heffter Institute, which is supporting the NYU study. "The whole hippie thing in the 60s" and media coverage at the time "has kind of left a bad taste in the mouth of the public at large.

"When you tell people you're treating people with psychedelics, the first thing that comes to mind is Day-Glo art and tie-dyed shirts."

Nothing like that was in evidence the other day when Edlich revisited the room at NYU where she'd taken psilocybin. Landscape photos and abstract art hung on the walls, flowers and a bowl of fruit adorned a table near the window. At the foot of the couch lay an Oriental rug.

"The whole idea was to create a living room-like setting" that would be relaxing, said study leader Dr. Stephen Ross.

Edlich, whose cancer forced her to retire from teaching French at a private school, had plenty of reason to seek help through the NYU project. Several recurrences of her ovarian cancer had provoked fears about suffering and dying and how her death would affect her family. She felt "profound sadness that my life was going to be cut short." And she faced existential questions: Why live? What does it all mean? How can I go on?

"These things were in my head and I wanted them to take a back seat to living in the moment," she said. So when she heard NYU researchers speak about the project at her cancer support group, she was interested.

Psilocybin has been shown to invoke powerful spiritual experiences during the four to six hours it affects the brain. A study published in 2008, in fact, found that even 14 months after healthy volunteers had taken a single dose, most said they were still feeling and behaving better because of the experience. They also said the drug had produced one of the five most spiritually significant experiences they'd ever had.

Experts emphasize people shouldn't try psilocybin on their own because it can be harmful, sometimes causing bouts of anxiety and paranoia.

The NYU study is testing whether that drug experience can help with the nine months of psychotherapy each participant also gets.

The therapy seeks to help patients live fuller, richer lives with the time they have left.

Each study participant gets two drug-dose experiences, but only one of those involves psilocybin; the other is a placebo dose of niacin, which makes the face flush.

The homey NYU room where Edlich had been getting psychotherapy was the setting for her drug experiences. She had brought along photos of her son, grandchildren and partner. She met with two therapists she'd come to trust, knowing they would stay with her through her hours under the influence.

Taking the drug followed a ritual, including the chalice and the hand-holding, because ritual has been part of psilocybin's successful use for centuries by traditional cultures, said Ross, the lead researcher.

After swallowing the white pill, Edlich perused an art book for about a half-hour while waiting for the psilocybin to take effect. Then she lay on the couch with headphones and listened to music with eyeshades over her eyes.

After her vision of the brilliantly colored dome, Edlich went on to two more experiences involving parts of her life. She won't describe those much, even to friends. They "brought me profound sadness and profound grief" but also transformed her understanding of what was important to her in the areas of relationships and trusting, she says.

She sat up and talked with her psychotherapists about what had gone on. And after nine hours in that room, she went home and wrote 30 pages in a diary about what had happened. And she thought about it for weeks afterward.

Did the drug experience help?

It let her view the issues she was working on through a different lens, she said.

"I think it made me more aware of what was so important and what was making me either sad or depressed. I think it was revelatory."

All three people in the study so far felt better, with less general anxiety and fear of death, and greater acceptance of the dying process, Ross said. No major side effects have appeared. The project plans to enroll a total of 32 people.

Ross' work follows up on a small study at the University of California, Los Angeles; results haven't been published yet, but they too are encouraging, according to experts familiar with it.

Yet another study of psilocybin for cancer anxiety, at Johns Hopkins University, has treated 11 out of a planned 44 participants so far. Chief investigator Roland Griffiths said he suspected the results would fall in line with the UCLA work.

In interviews, some psychiatrists who work with cancer patients reacted coolly to the prospects of using psilocybin.

"I'm kind of curious about it," said Dr. Susan Block of the Dana-Farber Cancer Institute in Boston. She said it's an open question how helpful the drug experiences could be, and "I don't think it's ever going to be a widely used treatment."

Ross, meanwhile, thinks patients might benefit from more than one dose of the drug during the psychotherapy. The study permits only one dose, but all three participants asked for a second, he said.

Edlich said her single dose "brought me to a deeper place in my mind, that I would never have gone to ... I feel a second session would even take me to more important places.

"I would do it a second time in a New York minute."